Ranbaxy slumps, Sun Pharma surges on $3.2b acquisition

Shares in Ranbaxy Laboratories Ltd fell as much as 3.2 percent on profit-taking after

RELATED ARTICLES

Sun Pharmaceutical Industries said it will buy the company in a $3.2 billion all-share deal, creating the world's fifth-largest generic drug maker.

Ranbaxy shares had surged 32.6 percent in six consecutive sessions of gains till Friday's close.

Sun Pharmaceutical shares rose as much as 4 percent.

Under terms of the agreed deal, Ranbaxy shareholders will get 0.8 of a Sun Pharmaceutical share for each Ranbaxy share they own. Daiichi Sankyo (4569.T) said in a statement that it will hold a stake of about 9 percent in Sun Pharmaceutical after the deal.

Post new comment

E-mail ID will not be published
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

EDITORIAL OF THE DAY

  • It will take at least 4 more quarters for corporate bottomlines to turn around

    Aggregate numbers from corporate results in the June quarter of 2014-15 are hardly different from the previous six quarters, with no positive surprise

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

Chander Mohan Sethi

CMD, Reckitt Benckiser India

COLUMNIST

Tushar Gandhi

Dealing with a sin called insensitivity

Rage and the notion of being above the law — ...

Kuruvilla Pandikattu SJ

India’s greatest gift to the world

What we hear most often about India these days is ...

Gautam Gupta

Why must innerwear be our best kept secret?

While women’s outerwear rules the marketing roost in India, unfortunately, ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture